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Abstract
Background: Decreases in direct maternal deaths in Jamaica have been negated by growing indirect deaths. With sickle cell
disease (SCD) a consistent underlying cause, we describe the epidemiology of maternal deaths in this population.
Methods: Demographic, service delivery and cause specific mortality rates were compared among women with (n=42) and
without SCD (n=376), and between SCD women who died in 1998–2002 and 2003–7.
Results: Women with SCD had fewer viable pregnancies (p: 0.02) despite greater access to high risk antenatal care (p: 0.001),
and more often died in an intensive care unit (p: 0.002). In the most recent period (2003–7) SCD women achieved more
pregnancies (median 2 vs. 3; p: 0.009), made more antenatal visits (mean 3.3 vs. 7.3; p: 0.01) and were more often admitted
antenatally (p:,0.0001). The maternal mortality ratio for SCD decedents was 7–11 times higher than the general population,
with 41% of deaths attributable to their disorder. Cause specific mortality was higher for cardiovascular complications,
gestational hypertension and haemorrhage. Respiratory failure was the leading immediate cause of death.
Conclusions: Women with SCD experience a significant excess risk of dying in pregnancy and childbirth [MMR: (SCD) 719/
100,000, (non SCD) 78/100,000]. MDG5 cannot be realised without improving care for women with SCD. Tertiary services
(e.g. ventilator support) are needed at regional centres to improve outcomes in this and other high risk populations.
Universal SCD screening in pregnancy in populations of African and Mediterranean descent is needed as are guidelines for
managing SCD pregnancies and educating families with SCD.
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Introduction
While maternal mortality has declined in Jamaica,[1] due
mainly to efforts aimed at reducing direct deaths, the contribution
from indirect deaths has risen from 17% in 1993–1995 to 31% in
2001–2003 (Figure 1), with sickle cell disease (SCD) a consistent
associated condition or underlying cause.
SCD is the commonest genetic disorder in Jamaica, with 10% of
the population carrying the S sickle gene. Among live born infants,
0.33% are homozygous SCD (SS) and 0.67% have some form of
SCD.[2] The disease is associated with high lifetime rates of
morbidity and premature mortality. Complications of SCD affect
every organ system and can be aggravated by pregnancy.[3] Better
quality of care for persons with SCD has improved survival and
thus the number of women entering the reproductive age group.
Reproduction however, is less efficient in this population. Sergeant
et al reported lower fecundity among women with SS compared to
those with heterozygous SCD (SC) or the normal genotype (AA),
characterized by later median age at menarche and first
pregnancy, more spontaneous abortions, fewer live births and
lower mean birth weight and gestational age at delivery among
those able to conceive. Successful pregnancy outcomes were
reported for only 57% of SS women compared to 85% with SC
and 89% of AA controls. [4]
International experience with pregnancy outcomes in SCD has
been varied. In Bahrain, Rajab et al[5] reported that maternal
morbidity and mortality and perinatal losses are a significant
consideration in SCD pregnancies. El-Shafei et al declared them
as high-risk pregnancies requiring close specialist monitoring and
reported SCD to be the underlying cause of death in 12 of 37
(32%) maternal deaths.[6]
Among antenatal women of African descent in Massachusetts,
USA, the prevalence of SCD was 0.6%. They had higher rates of
fetal death: OR 2.2 (95% CI=1.2, 4.2), preterm delivery; 1.5
(95% CI=1.2, 1.8), low birth weight 1.7 (95% CI=1.1, 2.6), and
small for gestational age (SGA) babies 1.3 (95% CI=1.0, 1.7).[7]
The Cooperative Study of SCD has shown favourable outcomes,
with antepartum and intrapartum complication rates similar to
pregnancies in African-American women without SCD[8]
however 21% of women had SGA babies. Sun et al from Grady
Hospital in Georgia, USA [9] also reported favourable pregnancy
outcomes, however women experienced more intrauterine
growth retardation, antepartum hospitalizations, postpartum
infections and prematurity compared to those with the normal
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maternal mortality.
Women with SCD had similar levels of obstetric complications
(e.g. pre-eclampsia, urinary tract infection) as AA counterparts in
Nigeria, West Africa, a population with similar genetic roots as
ours.[10] Studies from the United States however suggest that
women with SCD had higher odds of complications such as the
hypertensive disorders of pregnancy, including pre-eclampsia[11]
stroke,[12] and venous thromboembolism.[13] Among severely ill
women admitted with multiple organ failure to a Havana hospital
between 1998 and 2006, half of whom died, sickle cell disease was
the leading medical complication.[14]
While theSickleCellUnit(SCU),atthe University Hospitalofthe
West Indies has been a centre of research, service and outreach for
persons living with this genetic disorder in Jamaica, most women
with SCD access the same antenatal services available to women
withoutSCD,especiallyresidents outsidethe Kingston Metropolitan
area. This study aims to describe the epidemiology of maternal
deaths among women with SCD over a decade acrossthe islandwho
access care through the general antenatal services, some of whom
may be referred to the SCU for consultation, to better understand
the needs of this population. The objectives of the study are to:
N Describe the demographic characteristics(age,parity, residence)
and obstetric experience (#pregnancies, #live births, compli-
cations) of SCD women with pregnancy related deaths and
compare these characteristics with non SCD women who also
died and across two 5 year periods (1998–2002; 2003–2007)
N Determine the immediate and underlying causes of deaths
among women with and without SCD and whether the causes
have changed over the two 5 year periods of observation
N Identify access to health service factors which may be
associated with risk of dying.
Methods
Ethics Statement
The study was granted ethical approval by the University of the
West Indies/ University Hospital of the West Indies Ethical
Committee. The study was designed and performed in adherence
with the Declaration of Helsinki.
Maternal deaths are a Class 1 Notifiable event to Ministry of
Health, Jamaica and assuchall maternal deaths arerecorded by the
Ministry. As such, no consent was needed to study this condition
Figure 1. Maternal mortality ratios (per 100 000 live births) in Jamaica, 1981–2006.
doi:10.1371/journal.pone.0026281.g001
Figure 2. Jamaica: Hospitals and health centres.
doi:10.1371/journal.pone.0026281.g002
Maternal Deaths and Sickle Cell Disease
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26281and access to these data was provided by the Directors of Family
Health Services and Epidemiology, Ministry of Health, Jamaica.
Procedures
The study employs data from the Jamaican maternal mortality
surveillance system, instituted in 1998. [15] An active surveillance
system, suspected maternal deaths are reported to the Ministry of
Health, and investigated by the local health team. A 2004
evaluation documented that from 1998 to 2003 increasing number
of cases were being reported, however first trimester deaths and
late maternal deaths, especially occurring on non-obstetric wards
and in the Accident and Emergency departments were more likely
to be missed.[15] These findings were used to improve the
surveillance system by explicitly including the reporting of late
maternal deaths, instituting surveillance in non-obstetric areas of
public hospitals, private facilities and in the community. Over 95%
of deliveries occur in public facilities.[16] Maternal deaths
reported from public hospitals between 1998 and 2007 were
independently validated by reviewing all hospital deaths in women
10–50 years to determine whether they were pregnancy related to
ensure that all such events were included in the database.
We examined whether there were qualitative differences in
access to care by health regions (south-east, northeast, west, and
south). Given the highly specialized need for care in this
population, we also examined whether there were mortality
differences according to the highest level of care (access to care) in
the women’s parish of residence. This is defined as tertiary care,
where hospitals provide intensive care (ICU), including ventilator
support, limited to three parishes: Kingston, St Andrew and St
James; comprehensive obstetric (referral) care, with obstetric and
paediatric consultants based at regional hospitals (St Mary, St
Ann, Westmoreland, Manchester, St Catherine); and midwifery
care only, where delivery services in the parish are provided by
midwives, supported by a surgeon for emergency Caesarean
section (remaining five parishes: St Thomas, Portland, Trelawny,
Hanover, St Elizabeth). Complicated cases from these parishes
should be transferred to the nearest regional or tertiary hospital
(See Figure 2).
The causes of death and complications were coded using ICD
10. Underlying causes were combined into major groupings and
classified as direct, indirect or due to complications of treat-
ment.[17] The immediate cause of death was summarized
according to organ system dysfunction criteria.[18]
To determine how many antenatal women had SCD, we
utilized Ministry of Health data on the prevalence of SCD in their
antenatal population. Since 2001 (Appendix S1), women are
screened for anaemia and the sickling disorder; among those
failing the screen, electrophoresis is done to determine their
genotype. From 2001–7, 1.57% of first antenatal visits or 1.0% of
registered live births were positive for HbSS or HbSC. Applying
these prevalence rates to births over the decade leads to an
estimated 4863 to 7617 women with SCD who gave birth over the
period. Maternal mortality ratios (deaths/100 000 live births) were
computed using both estimates of the SCD population.
Statistics
A ‘Reproductive Index’ was calculated to determine the
proportion of pregnancies reaching viability (Parity/Gravidity).
Descriptive statistics are reported as frequency and percent for
categorical data and compared using x
2 test or Fisher’s exact test,
as appropriate. Continuous data are reported as mean and
standard deviation (SD) or median and interquartile range (IQR),
and compared by Student’s t test. Data were analysed using
STATA
TM 10.0 (StataCorp, College Station, Texas, USA).
Results
Of 538 pregnancy related deaths identified from 1998–2007,
50 (9.3%) occurred in women with SCD. Consistent with the
WHO definition of maternal death, exclusions included 15
women whose interval between delivery and death was unknown
(three SCD, 12 non SCD); 88 late deaths (five SCD, 83 non
SCD rpar; and 17 non SCD coincidental deaths, yielding a study
population of 42 (SCD) and 376 non SCD cases for analysis
(Figure 3).
SCD deaths
The mean age of SCD women was 27.5 years (range: 17–37
years). The genotype was SS in 40 and SC in the remaining 2
women. Median parity was 1 (range 0–4) and gravidity was 3
(range 1–5). Most deaths, (n=28, 67%) occurred in the south-east
region where 45% of births occur, with almost equal representa-
tion from the other three regions responsible for 10% (north-east),
10% (west) and 14% (south) of births. Most deaths (n=38; 90%)
occurred in hospital.
SCD versus non-SCD maternal deaths
Table 1 compares maternal deaths in women with and without
SCD. While there were no differences in the mean age nor the
number of pregnancies, women with SCD had significantly lower
parity, i.e. their reproductive index was significantly lower than
women without SCD. Those with SCD were more likely to be
enrolled in high risk antenatal care facilities, made almost twice as
many antenatal visits and had greater access to tertiary level care.
Significantly more SCD maternal deaths occurred in intensive
care facilities. There were however no differences in gestational
age at delivery or outcome of pregnancy.
SCD related maternal deaths during 1998–2002 versus
2003–2007
Women in the second study period tended to be older but not
significantly (Table 2); and achieved more successful pregnancies
than earlier (p=0.009). They had higher enrolment at high risk
Figure 3. Case selection process.
doi:10.1371/journal.pone.0026281.g003
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Jamaica: 1998–2007, by sickle cell disease (SCD) status.
Variable
All other maternal
deaths (n=376)
SCD maternal
deaths (n=42) p-value
Socio-demographic characteristics
Age in years (mean 6 SD) 29.467.2 27.565.6 0.103
Gravidity, Median (IQR) 3 (2–5) 3 (2–3) 0.2
Parity, Median (IQR) 2 (0–3) 1 (0–2) 0.01
Reproductive Index
* (mean6SD) 0.4460.3 0.3160.3 0.02
Access to care
Region of residence, n (%) 0.083
Southeast 171 (45.7) 28 (66.7)
Northeast 53 (14.2) 4 (9.5)
West 58 (15.5) 4 (9.5)
South 92 (24.6) 6 (14.3)
Highest level hospital facility in parish of residence, n (%) 0.01
Tertiary care 122 (33.1) 24 (57.1)
Referral obstetric care 121 (32.8) 11 (26.2)
Midwifery care 126 (34.1) 7 (16.7)
Antenatal care, n (%) 0.001
None reported 61 (16.2) 5 (11.9)
Primary health care 105 (27.9) 6 (14.3)
Hospital, high risk 82 (21.8) 22 (52.4)
Private doctor 53 (14.1) 5 (11.9)
Not known 75 (19.9) 4 (9.5)
Number of antenatal visits, (mean6SD) 3.2763.33 6.0364.42 ,0.0001
Attendant at delivery, n (%) 0.522
Traditional birth attendant/self 14 (4.8) 1 (2.9)
Registered midwife 63 (21.6) 4 (11.8)
Obstetrician 107 (36.6) 15 (44.1)
Other medical practitioner 108 (37.0) 14 (41.2)
Place of death, n (%) 0.002
Intensive care unit 41 (11.0) 14 (33.3)
Type a 147 (39.5) 14 (33.3)
Type b 92 (24.7) 6 (14.3)
Type c 62 (16.7) 4 (9.5)
Other 30 (8.1) 4 (9.5)
Pregnancy outcome
Days to death, n (%) 0.656
Pregnancy- 42 days post-partum
Undelivered 104 (28.7) 10 (24.4)
,24 hours 70 (19.3) 9 (22.0)
1–6 Days 97 (26.7) 14 (34.1)
7–42 Days 92 (25.3) 8 (19.5)
Outcomes of pregnancy, n (%) 0.512
Died undelivered 98 (27.4) 8 (19.5)
Early foetal loss 57 (15.9) 5 (12.2)
Stillbirth 52 (14.5) 6 (14.6)
Live birth 151 (42.2) 22 (53.7)
Survival of infant, n (%) 0.234
Yes 121 (32.2) 19 (45.3)
No 219 (58.2) 20 (47.6)
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26281antenatal care facilities (which were being developed and
expanded during this time period), made more antenatal visits,
had more antepartum hospitalizations and were more often
delivered by obstetricians. No differences were seen in gestational
age at delivery, place of delivery or death (although more died in
an ICU), or infant survival nor in the immediate or underlying
causes of death.
Table 3 shows that estimated maternal mortality ratios (MMR)
for women with SCD range between 551–719/100,000 compared
to 78/100,000 among non SCD women, a relative ratio of 7 to 11
times. Even after excluding the forty-one percent of deaths (17/42)
directly attributable to their sickling disorder, the relative risk
remains 4 to 6 times higher than in the general population and
represents the excess risk of dying in pregnancy attributed to SCD.
When we examine closely the cause specific rates, in addition to
their blood disorder, cardiovascular diseases were particularly
challenging. Worth noting is that over the 10 year period no
women with SCD died from endocrine disorders such as diabetes
or thyrotoxicosis. They also experienced higher rates of hyper-
tension and haemorrhage, the leading direct causes of death
among non SCD women (Figure 4a). Rates of complications of
treatment were much higher in the SCD population. The
immediate cause of death among SCD women ran the gamut of
organ failures, with respiratory failure, cardiac failure and
haematological complications including coagulopathy carrying
the highest odds, followed by hepato-renal failure (Figure 4b).
Over the two time periods, the MMR increased, but not
significantly (p value: 0.07), among SCD women from 628 to
1120/100 000 (Table 2).
Discussion
SCD remains a consistent cause of maternal mortality in
Jamaica[15] and other populations of African and Mediterranean
descent worldwide.[7,19,20,21,22] This is the largest series of
maternal deaths in women with SCD able to quantify the relative
difference in maternal mortality between women with SCD and
the general population. After accounting for deaths directly
attributed to their sickling disorder, the residual mortality ratio
of 328–428/100,000 represents the excess risk that SCD poses to
the childbearing population, a risk 4 to 6 times greater than in the
general population. This excess risk underscores the need for
urgent exploration of possible pathophysiological mechanisms to
inform appropriate interventions. Notwithstanding, the interaction
of abnormal rheology, leukocyte adhesion, endothelial dysfunction
and inflammation of SCD with the physiological changes of
pregnancy is of relevance.[23]
Case Identification
Over the 10 year review period 42 maternal deaths among
women with SCD were identified; 16 in the first five years, 26
in the latter. While increasing survival of women with SCD
into the reproductive age group may explain this difference,
it is also likely that with expansion in the high risk antenatal
clinic network and better antenatal screening, more at risk
women are being identified than previously. Limitations in
sample size made it difficult to record statistical changes in
clinical risks or outcomes over the two five year periods. We
assumed it was unlikely for a woman with SCD to enter the
reproductive age group without knowing she has SCD. Given
the high recurrent cost of private care, these women would be
regular users of public facilities and would either report their
status or be identified during pregnancy. The more conservative
estimate of the denominator for computing the MMRs uses their
prevalence among first visits to public antenatal clinics (7617) or
total births (4863).
While it is plausible that the clustering of cases in the south east
region, where the Sickle Cell Unit is located, might suggest that
families with affected persons may have relocated to this region to
access these services, it is also possible that greater sensitization of
the health team in this region has improved case identification, but
further research is needed to explore this.
Demographic characteristics
Consistent with data from Sergeant et al of reduced fecundity
in this population, [7] our data indicate fewer conceptions as
well. Over time it would appear that women were more willing
to attempt to have a baby, and the average number of
pregnancies increased between the first and second half of
the study. Given their lower fecundity, women with SCD may be
less interested in controlling their fertility and this might explain
their relatively high prevalence in public antenatal clinics in
excess of their expected distribution in the reproductive age
group.
Mortality risk
Bahrain reports a SCD prevalence similar to ours (0.9%)[24]
but a significantly lower MMR of 25/100,000,[19] and attributes
25–30% of their maternal deaths to SCD[6,19] compared to 10%
in our setting. Rajab[25] suggests a MMR of 1140/100,000 (4 of
351 births) in their women with SCD (similar to 1120/100 000 in
our second five year period). Without correcting for pregnancy
outcomes (stillbirths and live births), this ratio is also similar to
Serjeant’s experience in Jamaica[4] (1220/100 000), which would
Variable
All other maternal
deaths (n=376)
SCD maternal
deaths (n=42) p-value
Not known 36 (9.6) 3 (7.1)
Gestational age in weeks at termination of pregnancy/death (mean6SD) 29.960.1(n=302) 32.46.7(n=36) 0.15
Trimester pregnancy ended/death 0.268
First (0–14 weeks) 57 (16.6) 3 (7.3)
Second (15–28 weeks) 70 (20.4) 8 (19.5)
Third (29+ weeks) 216 (63.0) 30 (73.2)
Birth Weight of live born infants, kgs(mean6SD) 2.55698(n=116) 2.6260.94(n=19) 0.74
*Calculated as Parity/ Gravidity: Defined as the proportion of pregnancies reaching viability.
doi:10.1371/journal.pone.0026281.t001
Table 1. Cont.
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Variable 1998–2002(n=16) 2003–2007(n=26) p-value
Socio-demographic characteristics
Age in years (mean6SD) 25.967.1 28.564.4 0.197
Gravidity, Median (IQR) 2 (1–3) 3 (3–4) 0.009
Parity, Median (IQR) 0 (0–1) 1 (0–2) 0.25
Reproductive Index
* (mean6SD) 0.2560.29 0.3460.29 0.375
Access to care
Region of residence, n (%) 0.821(Fishers)
Southeast 11 (68.8) 17 (65.4)
Northeast 1 (6.2) 3 (11.5)
West 1 (6.2) 3 (11.5)
South 3 (18.8) 3 (11.5)
Highest level hospital facility in parish of residence, n (%) 0.680 (Fishers)
Type a (tertiary care) 10 (62.5) 14 (53.8)
Type b (referral obstetric care) 3 (18.8) 8 (30.8)
Type c (midwifery care) 3 (18.8) 4 (15.4)
Antenatal care, n (%) 0.008 (Fishers)
None reported 2 (12.5) 3 (11.5)
Primary health care 4 (25.0) 3 (11.5)
Hospital, high risk 4 (25.0) 18 (69.2)
Private doctor 2 (12.5) 3 (11.5)
Not known 4 (25.0) 0 (0.0)
Number of antenatal visits, (mean6SD) 3.2762.8 7.2964.5 0.01
Ante partum admission, n (%) ,0.0001(Fishers)
Yes 0 (0.0) 15 (57.5)
No 16 (100.0) 11 (42.3)
Attendant at delivery, n (%) 0.074(Fishers)
Traditional birth attendant/self 1 (8.3) 0 (0.0)
Registered midwife 1 (8.3) 3 (20.8)
Obstetrician 3 (16.7) 12 (54.2)
Other medical practitioner 8 (66.7) 6 (25.0)
Place of delivery, n (%) 0.847(Fishers)
Tertiary hospital 11 (68.2) 14 (66.7)
Referral hospital 2 (12.5) 5 (23.8)
General hospital 1 (5.6) 1 (4.8)
Private hospital 1 (5.6) 1 (4.8)
Home 1 (5.6) 0 (0.0)
Place of death, n (%) 0.35
Intensive care unit 3 (18.8) 11 (42.3)
Tertiary hospital 8 (50.0) 6 (23.1)
Referral hospital 2 (12.5) 4 (15.4)
General hospital 2 (12.5) 2 (7.7)
Other 1 (6.2) 3 (11.5)
Pregnancy outcome
Days to death, n (%) 0.233(Fishers)
Pregnancy- 42 days post-partum
Undelivered 6 (40.0) 4 (15.4)
,24 hours 4 (26.7) 5 (19.2)
1–6 Days 3 (20.0) 11 (42.3)
7–42 Days 2 (13.3) 6 (23.1)
Outcome of pregnancy, n (%) 0.862(Fishers)
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100 000).
The range of estimated maternal mortality among SCD women
of between 551 and 719 compared to 78/100 000 in the general
population demonstrates a 7 to 11 fold odds of dying in pregnancy.
The upper estimate is consistent with prevalence data where 10%
of deaths occurred among women with SCD who at birth made up
less than 1% (1 in 150) of the population. The lower estimate is
restricted to the population using public antenatal clinics. With an
overall MMR of 87/100,000, it is not possible to reduce our
maternal mortality ratio from 120 to 35 in keeping with the
MDG5 goal, without improving the quality of care to this and
other high risk populations.
Access to obstetric referral care
In 1998 the Ministry of Health rolled out a national high risk
antenatal care system[26,27] to improve referral of women at risk
of pregnancy complications for management by the obstetric
teams at regional hospitals (see Figure 2). By 2002, 85% of
antenatal women could access specialist care, although women
had to travel beyond their usual community of residence. This
increased access is reflected in the growth in SCD women using
such services between 1998–2002 and 2003–07 (22% and 65%
respectively).
Much of the emergency services required by women with SCD
currently reside in tertiary facilities, far from where most women
live. At minimum, ventilator support is needed in these facilities
and will benefit other high risk women (e.g. hypertensive disorders,
hemorrhage) who need short term access but for whom transfer to
tertiary centres may not be efficient enough to save their lives and
where there is already an increasing demand for ICU beds (with
an ageing population, increasing trauma, etc.). The relative
contribution of high risk women will only increase as more
women delay childbearing into years when chronic diseases
develop and as more women survive with these chronic disorders
and attempt to reproduce.
Quality of care
Most ‘delays’ [28] in care were due to patient factors or quality
of care once the patient had been seen, with limitations in
Variable 1998–2002(n=16) 2003–2007(n=26) p-value
Died undelivered 4 (26.7) 4 (15.4)
Early fetal loss 2 (13.3) 3 (11.5)
Stillbirth 2 (13.3) 4 (15.4)
Live birth 7 (46.7) 15 (57.7)
Survival of infant, n (%) 0.563
Yes 6 (37.5) 13 (50.0)
No 8 (50.0) 12 (46.2)
Not known 2 (12.5) 1 (3.8)
Gestational age in weeks at termination of pregnancy/death
(mean6SD)
31.567.5(n=13) 32.968.0(n=23) 0.627
Trimester pregnancy ended, n (%) 0.741(Fishers)
0–14 weeks 1 (6.7) 2 (7.7)
15–28 weeks 4 (26.7) 4 (18.2)
29+ weeks 10 (66.7) 20 (76.9)
Birth Weight of live born infants, kgs(mean6SD) 2.3160.60 (n=5) 2.9160.74(n=9) 0.143
Maternal mortality ratio 627.7 1119.7 1.78 (0.92–3.6)0.07
*Calculated as Parity/ Gravidity: Defined as the proportion of pregnancies reaching viability.
doi:10.1371/journal.pone.0026281.t002
Table 2. Cont.
Figure 4. Odds Ratios for death in SCD by Underlying causes (4a) and Immediate causes (4b) of death.
doi:10.1371/journal.pone.0026281.g004
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access improved ventilator support in the later period, these
resources need to be better distributed as patients must be
transferred to Kingston (south east) or Montego Bay (west).
Common immediate causes of death were respiratory failure,
coagulation defects and heart failure. Given the often acute and
sudden deterioration in these patients, present efforts should be
made to attend to their inpatient needs at tertiary facilities with
ICUs.
A major challenge is ensuring that these women, their partners
and families are educated about the risks to the mother and the
genetic likelihood of passing the condition to their offspring. A
comprehensive, integrated range of services should include family
planning; preconception counselling to include partner screening
and specialized antenatal care. The latter should include careful
monitoring, education and counseling; appropriate dietary advice
and supplementation; early identification of complications and
problems; specialist medical care, appropriate pain control,
physiotherapy and emergency obstetric care to ensure a successful
and healthy pregnancy and delivery with minimum disease related
complications.[29–30]
Conclusion and recommendations
Access to high risk antenatal services and intensive care has
improved in Jamaica but SCD continues to be a huge contributor
to maternal mortality. Extensive education and counselling of
women with SCD, their partners, and families contemplating
pregnancy and during pregnancy is needed alongside better
identification of SCD women early in pregnancy (comprehensive
screening). Guidelines need to be created for all healthcare
professionals to improve management of these women during
pregnancy. Referral centres need reliable supplies of blood and
blood products, ventilators, ability to screen for possible compli-
cations with use of e.g. echocardiography routinely during
pregnancy, and must continue to closely follow-up of women
postnatally.
Table 3. Cause specific underlying and immediate maternal mortality ratios per 100 000 live births, by sickle cell status, Jamaica,
1998–2007.
Underlying and immediate
causes of death Sickle cell maternal deaths
All other maternal
deathsMMR (deaths) Odds ratio (95% CI)
MMR (deaths)
Conservative
estimate MMR
Conservative
estimate
Underlying cause of death
TOTAL 718.8 (42) 551.4 77.8 (376) 11.1 (7.9 – 15.3) 7.1 (5.0–9.7)
Excluding blood disorders 427.9 (25) 328.2 77.6 (375) 6.6 (4.2–9.9) 4.2 (2.7–6.3)
Medical 555.2 (27) 354.5 24.4 (118) 22.7 (14.4–34.8) 14.4 (9.1–22.1)
Blood disorders 349.6 (17) 223.2 0.2 (1) 1690 (265–70608) 1073 (168–44824)
Cardiovascular 102.8 (5) 65.6 7.4 (36) 13.8 (4.2–35.3) 8.8 (2.7–22.4)
HIV/AIDS 41.1 (2) 26.3 4.3 (21) 9.5 (1.1–38.8) 6.0 (0.7–24.6)
Respiratory 20.6 (1) 13.1 1.9 (9) 11.1 (0.25–79.7) 7.0 (0.16–50.6)
Endocrine 0 3.1 (15) - -
Other indirect 41.1 (2) 26.3 7.4 (36) 5.5 (0.64–21.5) 3.5 (0.4–13.6)
Obstetric 246.8 (12) 157.5 47.4 (229) 5.2 (2.6–9.3) 3.3 (1.7–5.9)
Hypertensive 82.3 (4) 52.5 17.8 (86) 4.6 (1.2–12.3) 2.9 (0.78–7.8)
Hemorrhagic 61.7 (3) 39.4 8.7 (42) 7.1 (1.4–22.2) 4.5 (0.89–14.1)
Embolism 20.6 (1) 13.1 7.4 (36) 2.8 (0.07–16.4) 1.8 (0.04–10.4)
Other direct 82.3 (4) 52.5 13.4 (65) 6.1 (1.6–16.4) 3.9 (1.0–10.4)
Complications of treatment 61.7 (3) 39.4 6.0 (29) 10.3 (2.0–33.2) 6.5 (1.2–21.1)
Immediate cause of death (organ system failure)
Respiratory 329.0 (16) 210.1 18.6 (90) 17.7 (9.7–30.3) 11.2 (6.2–19.2)
Hematologic 205.6 (10) 131.3 18.4 (89) 11.2 (5.2–21.5) 7.1 (3.3–13.7)
Cardiac 164.5 (8) 105.0 13.0 (63) 12.6 (5.2–26.4) 8.0 (3.3–16.8)
Metabolic 102.8 (5) 65.6 11.0 (53) 9.4 (2.9–23.3) 6.0 (1.9–14.8)
Immunologic 41.1 (2) 26.3 7.0 (34) 5.9 (0.68–22.8) 3.8 (0.4–14.5)
Cerebral 20.6 (1) 13.1 7.2 (35) 2.9 (0.07–16.9) 1.8 (0.04–10.7)
No immediate cause stated 0 2.5 (12) - -
Estimated births 4863
a 7617
a 483 387
Non significant differences in italics.
aMinistry of Health antenatal screening data, % of women screened for anaemia who have HbSS/SC disease, as a percent of all births: 2001–2007 (1.0%) (Table 3).
bMinistry of Health antenatal screening data, % of all first visits screened who have HbSS/SC disease, 2001–2007 (1.57%) – intention to treat, and applied to total
registered live births to estimate births in SCD population (Table 3).
doi:10.1371/journal.pone.0026281.t003
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